Pediatr. praxi. 2020;21(6):426-428 | DOI: 10.36290/ped.2020.089

Ceftazidime/avibactam as a possible treatment in gram-negative nosocomial sepsis in a premature newborn

MUDr. Hana Wiedermannová^1,2, MUDr. Pavla Zárubová¹, MUDr. Václava Adámková^3,4, , MUDr. Hana Burčková¹, MUDr. Jan Pavlíček, Ph.D.^5,6

¹ Oddělení neonatologie, FN Ostrava

² Lékařská fakulta, Ostravská Univerzita, Ostrava

³ Ústav lékařské biochemie a laboratorní diagnostiky VFN, Praha

⁴ Ústav lékařské mikrobiologie LF Univerzity Palackého, Olomouc

⁵ Klinika dětského lékařství, FN Ostrava

⁶ Centrum biomedicínského výzkumu, FN Hradec Králové

Nosocomial infection is a serious diagnosis and the increase in the incidence of resistant bacterias significantly affects the mortality and morbidity of patients. Developed and new antibiotics are usually not recommended for early childhood or we have insufficient experience with them. One of the novel antibiotic is Ceftazidime/avibactam, containing broad-spectrum cephalosporin III. generation ceftazidime and the non-betalactam β-lactamase inhibitor avibactam. The use of this antibiotic in Gram-negative nosocomial sepsis caused by Klebsiella pneumoniae in the premature neonate is presented. Indication of this antibiotic led to the management of sepsis and there were no complications. The use of the antibiotic Ceftazidime/avibactam in severe infections is considered possible in pediatrics, including the category of immature newborns.

Keywords: ceftazidim, avibactam, neonate, nosocomial sepsis.

Published: January 6, 2021  Show citation